The global endobronchial ultrasound biopsy market is estimated at USD 0.80 billion in 2026 and is projected to reach USD 1.48 billion by 2036, expanding at a 6.3% CAGR during the forecast period. The market is gaining from wider use of minimally invasive mediastinal staging, expanding lung cancer screening programs, and increasing adoption of image-guided tissue sampling in hospitals and specialty pulmonary centers.

Endobronchial ultrasound biopsy combines bronchoscopy with real-time ultrasound imaging to guide tissue sampling from mediastinal lymph nodes and pulmonary lesions. Fact.MR estimates that the market will add approximately USD 0.73 billion between 2026 and 2036. Early growth is supported by increased CP-EBUS adoption in academic hospitals, while broader deployment in community hospitals and specialty pulmonary clinics is expected to support demand through the middle of the forecast period.

Get detailed market forecasts, competitive benchmarking, and pricing trends: https://www.factmr.com/connectus/sample?flag=S&rep_id=14422

EBUS scopes remain a core equipment category

EBUS scopes are projected to account for approximately 36% of the global market. Their position reflects their role as the central capital equipment used to combine bronchoscopy with real-time ultrasound imaging during guided tissue sampling. As hospitals expand minimally invasive diagnostic capabilities, demand for systems offering imaging clarity and compatibility with dedicated biopsy needles remains relevant to pulmonary and thoracic oncology workflows.

Convex-probe linear EBUS systems are expected to hold nearly 45% of the procedure outlook. These systems enable transbronchial needle aspiration under direct ultrasound guidance, making them particularly relevant for mediastinal lymph node staging and diagnosis. Their adoption also reflects the clinical preference for procedures that can reduce dependence on surgical biopsy approaches in appropriate diagnostic pathways.

The market is also moving toward greater integration between imaging, navigation, and tissue-sampling technologies. Advanced imaging processors, disposable EBUS-TBNA needles, and integration with robotic bronchoscopy systems are expected to influence value creation as healthcare providers seek more precise and efficient diagnostic workflows.

Shambhu Nath Jha, Principal Consultant at Fact.MR, notes that the report can help CXOs understand how lung cancer staging protocols, reimbursement dynamics, and integration with advanced imaging platforms are shaping demand for EBUS capital equipment and consumables.

China and India lead country-level growth

China is projected to record the highest CAGR among the countries covered, expanding at 8.5% through 2036. Growth is supported by expanding tertiary-care infrastructure, increasing oncology diagnostics, and greater installation of advanced bronchoscopy equipment. India follows with a 7.9% CAGR, driven by rising lung cancer incidence, expanding tertiary hospitals, and wider access to advanced pulmonary diagnostic services.

Germany is expected to grow at 7.2% CAGR, supported by structured cancer diagnostic pathways and established pulmonology services. France is projected to expand at 6.6%, while the United Kingdom is forecast to record a 6.0% CAGR as hospitals continue to optimize lung cancer referral and diagnostic pathways.

In North America, the United States is projected to grow at 5.4% CAGR through 2036. Demand remains linked to established tertiary oncology centers, advanced hospital infrastructure, lung cancer screening, and the continued use of minimally invasive pulmonary diagnostics. Brazil is expected to record a 4.7% CAGR as oncology diagnostic capacity gradually expands across urban healthcare centers.

Asia Pacific remains the fastest-growing regional market, with China and India serving as major contributors. Growing oncology infrastructure, physician training, hospital investments, and wider access to advanced bronchoscopic equipment are shaping procurement decisions across the region.

Competitive landscape

The competitive environment includes established medical technology companies with portfolios spanning endoscopic visualization, ultrasound imaging, biopsy instruments, and integrated diagnostic platforms. Key companies profiled by Fact.MR include Olympus Corporation, GE HealthCare, Siemens Healthineers AG, Koninklijke Philips N.V., Boston Scientific Corporation, Cook Group Incorporated, FUJIFILM Holdings Corporation, and Medi-Globe Technologies GmbH.

Competition is increasingly influenced by imaging resolution, biopsy precision, procedural reliability, regulatory compliance, and compatibility with broader pulmonary and oncology workflows. Manufacturers are also positioned around integration with robotic bronchoscopy, advanced imaging, and disposable consumables, allowing healthcare providers to build more connected diagnostic pathways.

Market Snapshot

The endobronchial ultrasound biopsy market is valued at USD 0.80 billion in 2026 and is forecast to reach USD 1.48 billion by 2036 at a 6.3% CAGR. EBUS scopes account for approximately 36% of the market, while convex-probe linear EBUS systems represent nearly 45% of the procedure outlook. Asia Pacific is identified as the fastest-growing region, led by China and India.

To View Top Reports

https://social.art-inpa.com/blogs/31973/Car-Rental-Market-Forecast-to-USD-263-41-Billion-by

https://sportgalax.com/read-blog/24379

https://sites.google.com/view/factmrinsights/report/car-rental-market-set-to-reach-usd-263-41-billion-by-2036-china-10-8-ind

https://afgbfh.blogspot.com/2026/10/car-rental-market-outlook-through-2036.html

About Fact.MR

Fact.MR is a market research and consulting company providing market intelligence, competitive analysis, and forecasting across global industries. Its research covers emerging technologies, evolving consumer trends, industrial developments, and changing business environments. Fact.MR delivers data-driven insights designed to support strategic planning, investment decisions, and market-entry initiatives.